Last Updated: November 16, 2026

Investigational Drug Information for ASP8062

« Back to Dashboard


What is the development status for investigational drug ASP8062?

ASP8062 is an investigational drug.

There have been 7 clinical trials for ASP8062. The most recent clinical trial was a Phase 2 trial, which was initiated on October 8th 2021.

The most common disease conditions in clinical trials are Substance-Related Disorders, Opioid-Related Disorders, and Disease. The leading clinical trial sponsors are Astellas Pharma Global Development, Inc., Astellas Pharma Inc, and National Institute on Drug Abuse (NIDA).

There are two US patents protecting this investigational drug and thirty-four international patents.

Recent Clinical Trials for ASP8062
TitleSponsorPhase
Human Laboratory Study of ASP8062 for Alcohol Use DisorderAstellas Pharma IncPhase 2
Human Laboratory Study of ASP8062 for Alcohol Use DisorderNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Phase 2
A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use DisorderAstellas Pharma Global Development, Inc.Phase 2

See all ASP8062 clinical trials

Clinical Trial Summary for ASP8062

Top disease conditions for ASP8062
Top clinical trial sponsors for ASP8062

See all ASP8062 clinical trials

International Patents for ASP8062

Drugname Country Document Number Estimated Expiration Related US Patent
ASP8062 Argentina AR098070 2033-10-17 ⤷  Start Trial
ASP8062 Australia AU2014335304 2033-10-17 ⤷  Start Trial
ASP8062 Canada CA2927518 2033-10-17 ⤷  Start Trial
ASP8062 China CN105636965 2033-10-17 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.